Kura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017
27 févr. 2017 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced an oral presentation for its lead product...
Kura Oncology to Participate in Three Upcoming Investor Conferences
09 févr. 2017 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief...
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
17 janv. 2017 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase...
Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 and Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program
04 janv. 2017 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...
Kura Oncology Appoints Steven Stein, M.D. to Board of Directors
03 janv. 2017 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced the appointment of Steven H. Stein, M.D., to its...
Kura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
01 déc. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today presented preclinical data highlighting the identification...
Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
15 nov. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company developing precision medicines for cancer, today announced it will...
Kura Oncology Reports Third Quarter 2016 Financial Results
07 nov. 2016 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Presents Update on Pipeline Programs Targeting RAS-ERK Pathway at European Scientific Oncology Conference
04 nov. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today presented preclinical findings and data from the company’s...
Kura Oncology to Participate in Two Upcoming Investor Conferences
01 nov. 2016 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and...